

ARCA biopharma, Inc.
Form 8-K
February 04, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 4, 2015 (February 4, 2015)

ARCA biopharma, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction

000-22873
(Commission

36-3855489
(I.R.S. Employer

of Incorporation)

File Number)

Identification No.)

11080 CirclePoint Road, Suite 140, Westminster, CO 80020

Edgar Filing: ARCA biopharma, Inc. - Form 8-K

(Address of Principal Executive Offices) (Zip Code)

(720) 940-2200

(Registrant's telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8 Other Events

Item 8.01. Other Events.

On February 4, 2015, ARCA biopharma, Inc. (ARCA) announced that the U.S. Patent and Trademark Office issued a patent on methods and compositions of the S-isomer formulation of Gencaro (bucindolol hydrochloride). The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.

Section 9 Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

| Number | Description |
|---------------|---|
| 99.1 | Press Release titled ARCA biopharma Announces Patent Issuance for Methods and Compositions of S-Isomer Formulation of Gencaro dated February 4, 2015. |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 4, 2015

ARCA biopharma, Inc.

(Registrant)

By: /s/ Christopher Ozeroff
Name: Christopher Ozeroff
Title: SVP and General Counsel

INDEX TO EXHIBITS

Exhibit

| Number | Description |
|---------------|---|
| 99.1 | Press Release titled ARCA biopharma Announces Patent Issuance for Methods and Compositions of S-Isomer Formulation of Gencaro dated February 4, 2015. |